Release
2021/06/16
OSAKA, Japan, June 16, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that Sage Therapeutics, Inc. (Head Office: Massachusetts, USA, CEO: Barry Greene) and Biogen Inc. (Head Office: Massachusetts, USA, CEO: Michel Vounatsos) issued positive Phase 3 results of zuranolone (Shionogi development compound number: S-812217), a therapeutic candidate for major depressive disorders.
Please refer the link below for details of the announcement.
[Press release]
https://www.businesswire.com/news/home/20210615005402/en/
[Investor slides]
https://investor.sagerx.com/static-files/ea6ab8b0-28e7-4f30-abfb-0222381eaf02
In Japan, Shionogi is currently conducting Phase 2 clinical trials for the indications of depression, and plan to obtain breaking data during the 2nd quarter of the fiscal year 2021.
Shionogi is committed to “improve social productivity and extend healthy lifespans” as our key focus. We will endeavor to deliver breakthrough treatments for the patients of psycho-neurological diseases including depression, which still have high unmet medical needs, and contribute to improving the QOL of patients and their families.
For Further Information, Contact:
SHIONOGI Website Iquiry Form : https://www.shionogi.com/global/en/contact.html